Soligenix achieves significant enrollment milestone for its pivotal phase 3 clinical trial
Soligenix announced it has reached a significant milestone in the Phase 3 clinical study for SGX942 (dusquetide) in treatment of oral mucositis in patients with head and neck cancer. Patient enrollment is sufficient to support the planned interim efficacy analysis by the independent DMC. April 18, 2019